March 26, 2019. NCHR testified at the FDA advisory committee meeting on Breast Implants on improving informed consent procedures for informing patients on risks of BIA-ALCL
Read More »On Health Policy
NCHR Comment on Proposed Draft Guidance Relating to Patient Experience Data
March 21, 2019. Patient perspectives and experience are important considerations for medical product development and regulation. Patients, caregivers, and patient and consumer groups can provide a valuable resource for product developers and the FDA. Transparency in how the FDA evaluates and uses proposed draft guidances as well as who and how they are developed will be important if they are to provide meaningful and accurate information about patients.
Read More »NCHR Comment on Management of Cybersecurity in Medical Devices
March 18, 2019. We support FDA’s efforts to update their approach to address growing concerns about cybersecurity risks in medical devices through the premarket submission process. Software and medical devices have become increasingly interconnected and vulnerable to network-related cybersecurity breaches, which puts patients at risk. We have several concerns and recommendations to improve the updated guidance.
Read More »NCHR Statement to the Maryland State House Environmental Committee, Artificial Turf
March 1, 2019. NCHR’s Jack Mitchell made a statement at the Maryland State House Environmental Committee regarding artificial turf and its negative effects.
Read More »Advancing Tobacco Control Practices To Prevent Initiation of Tobacco Use Among Youth and Young Adults, Eliminate Exposure to Secondhand Smoke, and Identify and Eliminate Tobacco- Related Disparities: Request for Information.
February 11, 2019 Tobacco use among youth and young adults is a large health concern. NCHR wrote a comment to the CDC regarding efforts to minimize usage among this population.
Read More »